TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04906434: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Sponsor: Abbisko Therapeutics Co, Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 200 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,419,032

Rescue Site Savings

+$1,602,216

Unlock Full NCT04906434 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04906434 Rescue Dossier →